Mutation detail:
| Mutation site | L106W/A150T |
| Virus | Human rhinovirus |
Mutation level  |
Amino acid level |
| Gene/protein/region type | VP1 |
| Gene ID | 1461213 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | B |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | NC_001490.1 |
| Drug/antibody/vaccine | LPCRW_0005 resisitant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Capsid Protein VP1 |
| Uniprot protein ID | P03303 |
| Protein length | 289 amino acids |
| Protein description | VP1 forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host ICAM1 to provide virion attachment to target host cells. |
Literature information:
| Pubmed ID | 24948704 |
| Clinical information | No |
| Disease | - |
| Published year | 2014 |
| Journal | Journal Of Antimicrobial Chemotherapy |
| Title | A novel benzonitrile analogue inhibits rhinovirus replication |
| Author | Celine Lacroix,Jordi Querol-Audi,Manon Roche,David Franco,Mathy Froeyen |
| Evidence | VP1_L106W, VP1_A150T and VP2_N20T for the first variant, and VP1_N105S, VP1_A150V and VP1_P155S for the second variant. |